×

Amicus Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference and 3rd Annual Dermatology Summit

CRANBURY, N.J., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of rare and orphan diseases, today announced that the Company will present at two conferences in San Francisco during the week of January 10 – 16, 2016.

34th Annual J.P. Morgan Healthcare Conference
John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 34th Annual J.P. Morgan Healthcare Conference 2016 on Tuesday, January 12, 2016 at 9:00 a.m. PT (12:00 p.m. ET). A live webcast of the J.P. Morgan presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.

3rd Annual Dermatology Summit
Jay Barth, Chief Medical Officer, will present an overview of the company’s late-stage program SD-101 for the treatment of Epidermolysis Bullosa (EB) at the 3rd Annual Dermatology Summit 2016 on Sunday, January 10, 2016. His presentation will be part of the Entrepreneurial Company Showcase: Presentations and Q&A to be held from 12:35 p.m. to 1:15 p.m PT. A copy of Dr. Barth’s slide presentation will be available at the start of the presentation through the Investors Section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm. For more information about this event please visit http://www.dermsummit.com/2016/.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and other lysosomal storage disorders.

FOLD–G

CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegrino Director, Investor Relations spellegrino@amicusrx.com (609) 662-5044 Media: Pure Communications Dan Budwick dan@purecommunicationsinc.com (973) 271-6085

Source:Amicus Therapeutics, Inc